What's Happening?
Convergent Therapeutics will present Phase 2 data from its CONVERGE-01 trial of CONV01-α at the 2026 ASCO Annual Meeting. The oral presentation will focus on patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with Lu-177
PSMA radioligand therapy. CONV01-α is a PSMA-targeted Ac-225 radioantibody designed to deliver localized alpha radiation to prostate cancer cells. The trial aims to assess the safety and efficacy of CONV01-α, offering insights into extending treatment benefits for mCRPC patients who have exhausted other options.
Why It's Important?
The presentation of CONV01-α's trial data is crucial for advancing treatment options for mCRPC, particularly for patients who have already received Lu-177 PSMA radioligand therapy. Convergent Therapeutics' focus on targeted radiotherapies could lead to improved outcomes and extended benefits for prostate cancer patients. The data from the CONVERGE-01 trial may support further development and potential regulatory submissions, expanding access to innovative therapies. Convergent's commitment to precision oncology highlights the importance of tailored treatments in addressing unmet needs in cancer care.
